Table 5 Regression Analysis
|  | Increase in percentage of words devoted to the reporting of safety in the results sectionŦ | Adequacy of reporting |
|---|---|---|
Predictors | Least-square regressions (Adjusted¥) Effect Size (95% CI) | Logistic regressions (Adjusted) OR (95% CI) |
Sample Size (per 10 unit increase) | 0.02 (-0.04-0.07) | 1.00 (1.00-1.00) |
Double Blind | 2.86 (-1.04-6.76) | 1.05 (0.47-2.31) |
Significant results for efficacy | -1.93 (-5.36-1.49) | 1.18 (0.03-1.40) |
Industry Funded | 0.27 (-4.04-4.58) | 2.49 (0.98-6.32) |
Longest duration to follow-up, ≥ 6 m | -0.07 (-4.04-3.91) | 0.99 (0.42-2.33) |
Paediatric population | -4.50 (-11.07-2.07) | 0.56 (0.11-2.90) |
Therapeutic studies | 3.21 (-0.84-7.26) | 1.81 (0.73-4.48) |
Combined studies | -0.32 (-4.03-3.39) | 0.79 (0.34-1.81) |
Multicentre | 4.02 (0.12-7.92)* | 1.89 (0.84-4.27) |
2009 Journal Impact Factor (per 10 unit increase) | 1.05 (-6.01-8.18) | 1.19 (0.98-1.43) |